A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Stopped early · Phase 1/Phase 2
Conditions studied: B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL
In brief
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX110 in subjects with relapsed or refractory B-cell malignancies.
Key facts
- Study ID
- NCT04035434
- Run by
- CRISPR Therapeutics AG
- People needed
- 93
- Starts
- 2019-07-22
- Expected to finish
- 2024-10-04
- Last updated by the study team
- 2025-10-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Cedars Sinai — Los Angeles, California, United States
- UCSF Medical Center — San Francisco, California, United States
- Mayo Clinic — Jacksonville, Florida, United States
- Emory University Winship Cancer Institute — Atlanta, Georgia, United States
- University of Chicago — Chicago, Illinois, United States
- University of Kansas — Westwood, Kansas, United States
- Markey Cancer Center, University of Kentucky — Lexington, Kentucky, United States
- University of Maryland — Baltimore, Maryland, United States
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
- University of Minnesota — Minneapolis, Minnesota, United States
- Washington University — St Louis, Missouri, United States
- Roswell Park Cancer Insitute — Buffalo, New York, United States
- Weill Cornell Medical College / New York Presbyterian Hospital — New York, New York, United States
- Duke University — Durham, North Carolina, United States
- Oregon Health and Science University — Portland, Oregon, United States
- Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
- Sarah Cannon Research Institute — Nashville, Tennessee, United States
- Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center — Dallas, Texas, United States
- Texas Transplant Institute — San Antonio, Texas, United States
- Virginia Commonwealth University Massey Cancer Center — Richmond, Virginia, United States
- Swedish Cancer Institute — Seattle, Washington, United States
- Royal Prince Alfred Hospital — Sydney, New South Wales, Australia
- Peter MacCallum Cancer Centre — Melbourne, Victoria, Australia
- Sir Charles Gairdner Hospital — Nedlands, Western Australia, Australia
- Princess Margaret Cancer Centre — Toronto, Ontario, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.